Proteostasis Therapeutics, Inc.

117 articles about Proteostasis Therapeutics, Inc.

• 

  Proteostasis Stock Surges on CF Fast Track Designation

  4/4/2018

  Company shares spiked 12.4 percent higher in premarket trading today after the U.S. Food and Drug Administration (FDA) granted Proteostasis Therapeutics’ triple combination for cystic fibrosis (CF) Fast Track Designation.

• Proteostasis Therapeutics Announces Withdrawal of Equity Offering Due to Market Conditions

  3/21/2018

  Proteostasis Therapeutics, Inc. announced that it is not proceeding with its proposed public offering of 9,000,000 shares of its common stock in an underwritten public offering previously announced on March 19, 2018.

• Proteostasis Therapeutics Announces Proposed Public Offering 9,000,000 Shares Of Common Stock

  3/19/2018

  Proteostasis Therapeutics, Inc. announced today that it intends to offer and sell, subject to market and other conditions, 9,000,000 shares of its common stock in an underwritten public offering.

• Proteostasis’ Proprietary Triple Combination Therapy Study Protocol Receives Endorsement and High Strategic Fit Score from the Largest Cystic Fibrosis Patient Advocacy Groups in the U.S. and Europe

  1/8/2018

  The CFF and ECFS are the most impactful CF patient advocacy organizations and shepherd the execution of clinical trials in the U.S. and Europe, respectively.

• Proteostasis Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

  12/22/2017

  Net proceeds from this offering were approximately $42.9M, after deducting underwriting discounts and commissions and estimated offering expenses.

• Proteostasis Therapeutics Prices Public Offering of Common Stock

  12/14/2017

  The gross proceeds to Proteostasis from the offering, before underwriting discounts and commissions and offering costs, are expected to be $40 million

• Proteostasis Therapeutics Announces Proposed Public Offering of Common Stock

  12/13/2017

  Leerink Partners LLC and RBC Capital Markets, LLC are acting as joint book-running managers for the offering.

• Proteostasis Therapeutics Announces Positive Clinical Results from Studies of PTI-428, PTI-801 and PTI-808 in Healthy Volunteers and Patients With Cystic Fibrosis

  12/12/2017

  The results support the goal of studying the Company’s novel CFTR modulators in doublet and triplet combinations in CF subjects.

• 

  Cambridge's Proteostasis Slashes R&D Jobs in Focus Shift

  11/2/2017

  As part of a strategic restructuring, Proteostasis is laying off 13 members of its R&D workforce.

• Proteostasis and Roche Ink Huge Space in New Boston Hub

  10/10/2017

• Proteostasis Appoints Helen M. Boudreau As Chief Financial Officer

  8/1/2017

• Proteostasis Announces Progression Of PTI-428 And PTI-801 To Longer Duration Studies In CF Subjects

  8/1/2017

• Proteostasis Reports Preliminary Data From Phase I Study Of PTI-428 In Patients With Cystic Fibrosis

  6/29/2017

• Proteostasis Files Investigational New Drug Application For PTI-808, Cystic Fibrosis Potentiator

  6/23/2017

• Proteostasis Announces Clinical And Regulatory Progress Across Pipeline Programs

  6/7/2017

• Proteostasis Reports Fourth Quarter And Year-End 2016 Financial Results And Provides Corporate Update

  3/31/2017

• Proteostasis Reports Third Quarter 2016 Financial Results

  11/10/2016

• Proteostasis Appoints Naimish Patel, M.D., C.M., And Elizabeth Tullis, M.D., FRCPC, To Its Clinical Advisory Board

  9/28/2016

• Proteostasis Announces Scientific Presentations On New Data At 30th Annual North American Cystic Fibrosis Conference

  9/22/2016

• Proteostasis To Present At Upcoming Investor Conferences

  9/16/2016